Department of Urology, Ewha Womans University College of Medicine, Seoul, Korea.
Department of Urology, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
Investig Clin Urol. 2019 Nov;60(6):425-431. doi: 10.4111/icu.2019.60.6.425. Epub 2019 Oct 1.
The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring biomarker of renal cell carcinoma (RCC).
Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients and controls.
RCC patients had higher serum PHD3 levels than controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL, p=0.023), with an area under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respectively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 months were significantly lower than the preoperative PHD3 levels (both p<0.001).
Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.
本研究旨在确定血清脯氨酰羟化酶-3（PHD3）作为肾细胞癌（RCC）诊断或监测生物标志物的适用性。
2013 年 10 月至 2015 年 3 月期间，我们前瞻性地招募了研究参与者。RCC 组包括 56 例接受根治性或部分肾切除术的患者。对照组包括 56 名健康肾脏供体和 13 名患有良性肾肿瘤的患者。在手术前和手术后 1 个月和 3 个月采集 RCC 患者的血液。通过酶联免疫吸附试验测量血清 PHD3 水平，并比较 RCC 患者与对照组之间的水平。
RCC 患者的血清 PHD3 水平高于对照组（0.79±0.17ng/mL 比 0.73±0.09ng/mL，p=0.023），曲线下面积（AUC）为 0.668。以 0.761ng/ml 为截断值，灵敏度、特异性、阳性预测值和阴性预测值分别为 66.1%、68.1%、28.8%和 37.3%。健康肾脏供体和患有良性肾肿瘤的患者之间的 PHD3 水平无显著差异。在肿瘤大小>2cm（n=40）或透明细胞组织学（n=44）的 RCC 患者亚组分析中，PHD3 的预测性能得到改善，AUC 分别为 0.709 和 0.688。在 37 例 PHD3 水平高于 0.761ng/ml 截断值的患者中，术后 1 个月和 3 个月的 PHD3 水平均明显低于术前 PHD3 水平（均 p<0.001）。
血清 PHD3 是一种新型的 RCC 生物标志物，具有可接受的诊断性能。
